PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Symptom | |diabetes |
| Sentences | 526 |
| PubMedID- 26180307 | Theage-adjusted incidence of hypertension and coronary heart disease was 38% and 24%,respectively, showing a clear incidence of diabetes associated with cardiovascular diseasein saudi arabia. |
| PubMedID- 24567354 | Increased white blood cell (wbc) count is related to cardiovascular disease in patients with type 2 diabetes mellitus; raised neutrophil lymphocyte ratio (nlr) is associated with metabolic syndrome. |
| PubMedID- 24396666 | Other recent reports showed that variations in long-term glycemia, defined as a1c variability, were powerful independent predictors for diabetic microvascular complications and even for cardiovascular disease (cvd) events in patients with type 1 diabetes . |
| PubMedID- 20591087 | diabetes leads to premature cardiovascular disease and is regarded by many as the most common etiological factor for chronic kidney disease. |
| PubMedID- 25328404 | Aim/introduction: circulating levels of n-terminal fragment of probrain natriuretic peptide (nt-probnp) are established as a risk factor for cardiovascular disease and mortality in patients with diabetes, as well as in the general population. |
| PubMedID- 22526620 | Poorly managed type 1 diabetes can lead to cardiovascular disease, diabetic neuropathy, and diabetic retinopathy. |
| PubMedID- 23730303 | Abnormal endothelial function is a salient feature of vascular disease in diabetes that is exemplified by a decrease in nitric oxide (no) synthesis or bioavailability. |
| PubMedID- 25923078 | Type 2 diabetes mellitus patients with cardiovascular disease showed higher expression of plasma retinol binding protein and glutathione peroxidase-3 compared to those without cardiovascular disease and non-diabetic controls. |
| PubMedID- 25527522 | Conclusions: in our series, type 2 diabetes mellitus patients with cardiovascular disease at baseline present with an increased risk of developing diabetic peripheral neuropathy at 10 years of follow-up. |
| PubMedID- 22373102 | Percutaneous therapy for limb-threatening lower extremity vascular disease with or without diabetes has no exception, with primary patency rates at 36 months of 46.5% and 60.9%. |
| PubMedID- 22496883 | This study provides new targets for drug development and new strategies for the prevention and treatment of vascular diseases in diabetes patients with hypertension. |
| PubMedID- PMC4484638 | Even though the exact mechanism for accelerated vascular disease in diabetes is not yet fully clear, existing research has defined numerous risk factors involved in diabetes, such as oxidative stress , dyslipidemia , advanced glycation . |
| PubMedID- 21035578 | There is also strong evidence that blood pressure targets for populations at high risk of cardiovascular disease, including those with diabetes, coronary artery disease, and chronic kidney disease, should be lower than 140/90 mm hg. |
| PubMedID- 24905298 | General significance: this strategy might prove clinically relevant in preventing the development and/or retarding the progression of diabetes associated with vascular diseases. |
| PubMedID- 21109113 | Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the advance (action in diabetes and vascular disease: preterax and diamicron modified-release controlled evaluation) trial. |
| PubMedID- 22474525 | A therapeutic effect of myricetin in patients with cardiovascular diseases associated with diabetes mellitus has also been reported . |
| PubMedID- 24462067 | Results of epidemiologic studies that investigated the significance of pulse pressure (pp) and mean arterial pressure (map) in terms of risk of cardiovascular disease (cvd) in patients with diabetes mellitus are inconsistent. |
| PubMedID- 26100640 | Nobody disputes the fact that type 1 diabetes increases the risk of death from cardiovascular diseases. |
| PubMedID- 23166795 | Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease. |
| PubMedID- 23275938 | proposed that the cut-off point for the bapwv in type 2 diabetes patients with cardiovascular disease was 1,635 cm/sec (sensitivity 73%, specificity 75%). |
| PubMedID- 21926285 | diabetes is associated with microvascular disease, white matter hyperintensities (wmhs), cerebral atrophy (1,2), and functional decline (3,4). |
| PubMedID- 22530043 | Furthermore, in that study, lvm regression was independently associated with improved patient survival even after adjustment for age, gender, diabetes, history of cardiovascular disease, and all nonspecific cardiovascular risk factors. |
| PubMedID- 26199685 | Background: diabetes is associated with increased cardiovascular disease, mortality and morbidity. |
| PubMedID- 20350283 | Despite the profound clinical importance of vascular disease in patients with diabetes mellitus, our understanding of the molecular and cellular mechanisms by which diabetes promotes these vascular complications is incomplete. |
| PubMedID- 25325279 | Many studies have reported postprandial hyperglycemia as a major cause of adverse cardiovascular disease in patients with diabetes mellitus . |
| PubMedID- 25899686 | Cirrhosis) is higher than that for cardiovascular disease among patients with diabetes . |
| PubMedID- 23082138 | Model ii: adjustment for the covariates mentioned above plus diabetes, history of hypertension, previous cardiovascular disease, and medication treatment. |
| PubMedID- 23878823 | Atherosclerosis that is often found in type 2 diabetes is a complication of macrovascular disease that increases the risk for myocardial infarction and strokes. |
| PubMedID- 19232762 | Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials. |
| PubMedID- 20601395 | Methods and results: one hundred and fifty type 2 diabetes patients with cardiovascular disease (cvd) or >/= 1 other cvd risk factor were randomized to receive rosiglitazone vs. |
| PubMedID- 20185811 | The present study includes 740 men and 777 women with diabetes who were free of cancer and cardiovascular disease at blood draw, and who had detectable lp-pla2 activity values. |
| PubMedID- 26313785 | A study by tobias et al20 reported results similar to ours with a j-shaped association across bmi categories for all-cause mortality in participants with incident diabetes who were free of cardiovascular disease and cancer at the time of a diagnosis of diabetes. |
| PubMedID- 25227555 | Impact of chronic kidney disease on the prevalence of cardiovascular disease in patients with type 2 diabetes in spain: percedime2 study. |
| PubMedID- 23144257 | Hypertension and diabetes are initial stages of cardiovascular disease, and the risk is elevated because of the high prevalence of tobacco smoking among men. |
| PubMedID- 24505486 | Further confining the analysis to participants with complete data for bmi, waist circumference, blood pressure, smoking status, diabetes status, history of cardiovascular disease, poverty:income ratio and time of day of venepuncture gave a total of n = 19,381 included in the analyses of serum phosphorus, total alp and estimated dietary phosphorus intake. |
| PubMedID- 22994452 | Regarding cardiovascular mortality, age, diabetes mellitus, history of cardiovascular disease, lvmi, lvef, cimt, and pwv were significant predictors (table2). |
| PubMedID- 26381503 | Erythropoiesis stimulating agent (esa) treatments targeting mild anemia (10-12 g/dl) can decrease the risk of occurrence of cardiovascular disease (cvd) in patients with hypertension, diabetes mellitus and congestive heart failure. |
| PubMedID- 23940992 | Study included 313 normoalbuminuric patients with type 1 diabetes, none showed signs of adrenal, renal, or cardiovascular diseases. |
| PubMedID- 24498934 | Ev-markers and the risk of new onset type 2 diabetes in patients with manifest cardiovascular disease. |
| PubMedID- 23844096 | The correlations between tat and patency remained significant after adjustment for age, diabetes, smoking, history of cardiovascular disease, and number of days since avf creation in a multivariate linear regression model. |
| PubMedID- 21468921 | To confirm the efficacy of metformin use on triglyceride level and hdl-c level associated with the risk of cardiovascular disease in patient with diabetes, further placebo-controlled investigations are required. |
| PubMedID- 20967275 | For example, chronic hypertension is primarily characterized by endothelial dysfunction and microvascular disease whereas with diabetes the pathology may be due to direct effects of hyperglycemia in addition to vascular disease. |
| PubMedID- 24616778 | (6) attempted to demonstrate direct causation by examining cardiac innervation using metaiodobenzylguanidine imaging in patients with diabetes and no history of cardiovascular disease. |
| PubMedID- 21080957 | Therefore, based on the findings from the present study and the accumulating body of clinical evidence with exenatide, therapy with glp-1 receptor agonists may represent a promising approach for the treatment of patients with chf or cardiovascular disease associated with type 2 diabetes, supporting the need for further research in this field. |
| PubMedID- 25790898 | Cardiovascular disease among women with and without diabetes mellitus and bilateral oophorectomy. |
| PubMedID- 23738538 | Among people with diabetes, the highest risk of death from cardiovascular disease is found in those treated with oral hypoglycemic drugs or insulin and in those with longer duration of diabetes . |
| PubMedID- 22701470 | Functional abnormalities of the vascular endothelial lining have been shown to precede overt cardiovascular disease in patients with and without diabetes . |
| PubMedID- 24651718 | Glp-1 receptor agonist represents a novel approach for the treatment of patients with cardiovascular disease associated with type 2 diabetes . |
| PubMedID- 21735134 | We prospectively studied 2,277 cardiac patients, and the results show high congruence between the markov model and the ph model; both evidence that diabetes, history of stroke, peripheral vascular disease and smoking significantly increase hazard rate and reduce survival time. |
| PubMedID- 22234950 | Sub-optimal achievement of guideline-derived lipid goals in management of diabetes patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies. |